Novelos Therapeutics, Inc. (NVLT) - Financial and Strategic SWOT Analysis Review

Document Sample
Novelos Therapeutics, Inc. (NVLT) - Financial and Strategic SWOT Analysis Review Powered By Docstoc
					              Novelos Therapeutics, Inc. (NVLT) - Financial and Strategic SWOT
                                      Analysis Review
        Reference Code: GDPH62534FSA                                                                                          Publication Date: AUG 2012

          3301 Agriculture Drive                             Phone              +1 608 4418120                  Revenue          NA
          Madison, WI                                        Fax                +1 608 4418121                  Net Profit       -7.44 (million USD)
          53716                                              Website            www.novelos.com                 Employees        18
                                                                                NVLT     [Over          The                      Pharmaceuticals           &
          United States                                      Exchange                                           Industry
                                                                                Counter]                                         Healthcare

       Company Overview
       Novelos Therapeutics, Inc. (Novelos) is a pharmaceutical company involved in developing novel drugs for the treatment and
       diagnosis of cancer. The company's therapeutic compounds directly kill cancer cells without harming normal cells. Novelos'
       product pipeline include three compounds, namely, CLR1401 (COLD), a pre-clinical cancer-targeted non-radioactive
       chemotherapy; I-131-CLR1404 (HOT), which acts as cancer-targeted delivery and retention vehicle, is in its Phase 1b dose-
       escalation trial; and I-124-CLR1404 (LIGHT), is a small-molecule cancer-targeted PET imaging agent and Phase 1-2 clinical trials
       are in progress.
       Key Executives                                                                SWOT Analysis
                      Name                                 Title                      Novelos Therapeutics, Inc., SWOT Analysis
         Harry S. Palmin                     Chief Executive Officer                  Strengths                              Weaknesses
         Jamey Weichert, Ph.D                Chief Scientific Officer
                                                                                      Strong Intellectual Property           History of Losses
         Stephen A. Hill                     Chairman                                 Portfolio
                                                                                                                             Legal Proceedings
         James S. Manuso, Ph.D               Director
                                                                                      Strategic Acquisition
         Howard M. Schneider                 Director
        Source: Annual Report, Company Website, Primary and Secondary
        Research, GlobalData                                                          Opportunities                          Threats

       Share Data                                                                     Products in Pipeline                   Growing competition
         Novelos Therapeutics, Inc.
                                                                                      Changing Demographics                  Uncertain R&D Outcomes
        Share Price (USD) as on 02-Aug-                                  1.03
        2012
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
        EPS (USD)                                                       -0.31        GlobalData
        Market Cap (million USD)                                           48
        Enterprise Value (million USD)                                     45
        Shares Outstanding (million)                                       38
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData

       Financial Performance                                                         Recent Developments
                                                                                      May 04, 2012         Novelos    Therapeutics      Reports     Q1     2012
                                                                                                           Results
                                                                                      Apr 03, 2012         Novelos     Therapeutics   And    Academic
                                                                                                           Collaborators Present Three Posters At 2012
                                                                                                           AACR Annual Meeting
                                                                                      Mar 09, 2012         Novelos Therapeutics Reports 2011 Results
                                                                                      Mar 01, 2012         Novelos     Therapeutics  And    Academic
                                                                                                           Collaborators To Present Three Abstracts At
                                                                                                           2012 American Association For Cancer
                                                                                                           Research Annual Meeting
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData                                                          Source: Annual Report, Company Website, Primary and Secondary Research,
                                                                                     GlobalData




Novelos Therapeutics, Inc. (NVLT) - Financial and Strategic SWOT                                                               Reference Code: GDPH62534FSA
Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                     Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Table of Contents
       Table of Contents ............................................................................................................................................................................... 2
          List of Tables .................................................................................................................................................................................. 4
          List of Figures ................................................................................................................................................................................. 4
       Section 1 - About the Company.......................................................................................................................................................... 5
       Novelos Therapeutics, Inc. - Key Facts .............................................................................................................................................. 5
       Novelos Therapeutics, Inc. - Key Employees ..................................................................................................................................... 6
       Novelos Therapeutics, Inc. - Key Employee Biographies ................................................................................................................... 7
       Novelos Therapeutics, Inc. - Major Products and Services ................................................................................................................ 8
       Novelos Therapeutics, Inc. - Pharmaceutical Pipeline Products Data ................................................................................................ 9
          Novelos Therapeutics, Inc., Pipeline Products by Therapy Area .................................................................................................... 9
          Novelos Therapeutics, Inc., Pipeline Products by Development Phase ........................................................................................ 10
       Novelos Therapeutics, Inc. - History................................................................................................................................................. 12
       Novelos Therapeutics, Inc. - Company Statement ........................................................................................................................... 13
       Novelos Therapeutics, Inc. - Locations And Subsidiaries ................................................................................................................. 15
          Head Office ................................................................................................................................................................................... 15
          Other Locations & Subsidiaries ..................................................................................................................................................... 15
       Section 2 – Company Analysis ......................................................................................................................................................... 16
       Novelos Therapeutics, Inc. - Business Description .......................................................................................................................... 16
       Novelos Therapeutics, Inc. - SWOT Analysis ................................................................................................................................... 17
          SWOT Analysis - Overview........................................................................................................................................................... 17
          Novelos Therapeutics, Inc. - Strengths ......................................................................................................................................... 17
             Strength - Strong Intellectual Property Portfolio ........................................................................................................................ 17
             Strength - Strategic Acquisition ................................................................................................................................................. 17
             Strength - Focused Research and Development Activities ....................................................................................................... 17
          Novelos Therapeutics, Inc. - Weaknesses .................................................................................................................................... 18
             Weakness - History of Losses ................................................................................................................................................... 18
             Weakness - Legal Proceedings ................................................................................................................................................. 18
          Novelos Therapeutics, Inc. - Opportunities ................................................................................................................................... 18
             Opportunity - Products in Pipeline ............................................................................................................................................. 18
             Opportunity - Changing Demographics ..................................................................................................................................... 18
             Opportunity - Market Potential: Oncology.................................................................................................................................. 18
          Novelos Therapeutics, Inc. - Threats ............................................................................................................................................ 19
             Threat - Growing competition .................................................................................................................................................... 19
             Threat - Uncertain R&D Outcomes ........................................................................................................................................... 19
             Threat - Stringent Government Regulations .............................................................................................................................. 19
       Novelos Therapeutics, Inc. - Key Competitors ................................................................................................................................. 20
       Section 3 – Company Financial Ratios ............................................................................................................................................. 21
       Financial Ratios - Capital Market Ratios........................................................................................................................................... 21
       Financial Ratios - Annual Ratios ...................................................................................................................................................... 21
       Performance Chart ........................................................................................................................................................................... 23
       Financial Performance...................................................................................................................................................................... 23
       Financial Ratios - Interim Ratios....................................................................................................................................................... 24
       Financial Ratios - Ratio Charts ......................................................................................................................................................... 25
       Section 4 – Company’s Lifesciences Financial Deals and Alliances ................................................................................................ 26
          Novelos Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2006 to YTD 2012.................................................. 26


Novelos Therapeutics, Inc. (NVLT) - Financial and Strategic SWOT                                                                                               Reference Code: GDPH62534FSA
Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                                                                Page 2
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
          Novelos Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2006 to YTD 2012 ................................................. 27
       Novelos Therapeutics, Inc., Recent Deals Summary ....................................................................................................................... 28
       Section 5 – Company’s Recent Developments ................................................................................................................................ 29
          Novelos Therapeutics, Inc., Recent Developments .......................................
				
DOCUMENT INFO
Description: Novelos Therapeutics, Inc. (Novelos) is a pharmaceutical company involved in developing novel drugs for the treatment and diagnosis of cancer. The company's therapeutic compounds directly kill cancer cells without harming normal cells. Novelos' product pipeline include three compounds, namely, CLR1401 (COLD), a pre-clinical cancer-targeted non-radioactive chemotherapy; I-131-CLR1404 (HOT), which acts as cancer-targeted delivery and retention vehicle, is in its Phase 1b dose-escalation trial; and I-124-CLR1404 (LIGHT), is a small-molecule cancer-targeted PET imaging agent and Phase 1-2 clinical trials are in progress. These three cancer-targeted compounds are selectively taken up and retained in cancer cells, including cancer stem cells versus normal cells. Novelos is headquartered in Madison, Wisconsin, the US.
BUY THIS DOCUMENT NOW PRICE: $125 100% MONEY BACK GUARANTEED
PARTNER GlobalData
GlobalData is an industry analysis specialist, providing business information products and services. GlobalData’s highly qualified team of analysts, researchers, and solution consultants use proprietary data sources, tools and techniques to gather, analyze and represent the latest and the most reliable information essential for a business to sustain a competitive edge. GlobalData is a UK-based company with presence across North America, Europe and Asia Pacific and has a broad product offering that ranges from interactive databases, reports and custom solutions. It is a comprehensive source of insights and analysis with coverage across the oil & gas, power, alternative energy, nuclear power, petrochemicals, medical equipment and healthcare industries. GlobalData has a broad range of coverage over key market segments. It has a global scope, covering a wide range of countries constituting more than 90% of global revenues in each of the industries it covers. With a large dedicated research and analysis capability, GlobalData employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries. Sectors and Geographies Covered GlobalData has a broad range of coverage over key market segments. It has a global scope, covering a wide range of countries constituting more than 90% of global revenues in each of the industries it covers. Research Methodology With a large dedicated research and analysis capability, GlobalData employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries.